Current Status of Drug-Eluting Stents in Coronary Heart Disease

1. Fundamental Role of DES in CHD Management

Percutaneous coronary intervention (PCI) with stent implantation is a cornerstone of revascularization in patients with symptomatic coronary artery disease (including stable angina and acute coronary syndromes).
DES were developed to limit in-stent restenosis (ISR)—the re-narrowing of the vessel after angioplasty—which was a major limitation of bare-metal stents (BMS). Multiple randomized trials and meta-analyses consistently demonstrate that DES significantly reduce restenosis and the need for repeat revascularization compared with BMS, without increasing mortality or myocardial infarction in the medium term. NCBI

2. Technological Evolution of DES

Generations of DES

1. First-generation DES:
   Sirolimus-eluting and paclitaxel-eluting stents markedly lowered ISR rates compared to BMS but were associated with concerns over delayed healing and late stent thrombosis due to durable polymer coatings. PubMed
2. Second-generation DES:
   These use more biocompatible durable polymers (e.g., everolimus, zotarolimus) and thinner struts. They offer improved safety (reduced thrombosis) and efficacy. INVAMED+1
3. Third and newer generations (as of 2025):
   • Biodegradable polymer DES: polymers that fully resorb after drug delivery
   • Polymer-free DES: drug release without a permanent polymer
   • Bioresorbable scaffolds (next-gen): aim to provide temporary support and then vanish, potentially restoring natural vessel function. INVAMED

Emerging Innovations

• Polymer-free and nanotechnology-enhanced drug delivery mechanisms to optimize controlled elution and reduce inflammation.
• Gradient and biomimetic polymers designed for tailored kinetics and endothelial healing.
• Multi-drug elution platforms targeting anti-proliferative, pro-healing, and anti-inflammatory pathways. INVAMED

The goal of these advancements is to further reduce restenosis and stent thrombosis while improving vascular healing and potentially shortening required duration of adjunctive antiplatelet therapy. Frontiers

3. Clinical Outcomes and Safety

Efficacy

• DES significantly lower ISR and need for repeat PCI compared with BMS.
• Long-term data (up to 5 years) show sustained benefits with modern DES with low rates of target lesion failure. PMC

Stent Thrombosis

• Rates of very late stent thrombosis have declined markedly (<1%) with newer generation DES using biocompatible polymers and thinner struts. The Pharmaceutical Journal
• Optimized implantation techniques (e.g., intravascular imaging like IVUS/OCT) further reduce risks related to underexpansion or malapposition. The Pharmaceutical Journal

Complex Lesion Subsets

Contemporary DES perform well in challenging anatomies—bifurcation lesions, chronic total occlusions, small vessels, and long lesions—with acceptable safety and efficacy profiles. INVAMED

4. Dual Antiplatelet Therapy (DAPT) and Current Practice

Antiplatelet therapy remains integral to DES management to reduce thrombotic risk. Traditionally, 6–12 months of DAPT (aspirin plus P2Y12 inhibitor) was recommended after DES implantation.

However, with newer DES designs and improved safety:

• Shorter DAPT regimens (1–3 months) followed by P2Y12 inhibitor monotherapy are increasingly validated in selected patients—particularly those at high bleeding risk—without significant increase in major adverse cardiac events. Frontiers

Optimal DAPT duration is individualized based on thrombotic versus bleeding risk.

5. Comparisons with Alternative Technologies

• Drug-Coated Balloons (DCB):
  In selected scenarios (e.g., small vessels, in-stent restenosis), DCBs offer a leaving nothing behind strategy without permanent implants. Comparisons with DES are ongoing, with some studies indicating equivalence or specific advantages in certain contexts. SpringerLink
• Bioresorbable Scaffolds:
  Next-gen bioresorbable platforms may reduce long-term scaffolding complications, but earlier versions showed higher early thrombosis risk. Ongoing trials are refining these technologies. PubMed

6. Current Clinical Guidelines and Indications

Current practice and guidelines support the use of DES as first-line devices for most PCI cases due to:

• Lower restenosis and revascularization rates
• Acceptable long-term safety profile
• Broader applicability, including complex and high-risk lesions with appropriate imaging guidance
  Guideline recommendations continue to evolve, informed by new outcomes data and evidence on DAPT duration, particularly after acute coronary syndromes.

7. Remaining Challenges and Future Directions

Challenges (ongoing research focus):

• Balancing endothelial healing with neointimal inhibition to further mitigate thrombosis risk
• Shortening DAPT without increasing thrombotic events
• Personalized stent selection based on lesion, patient risk, and vascular biology

Future directions include:

• Further refined drug release technologies
• Bioresorbable and fully polymer-free DES platforms
• Integration of artificial intelligence (AI) for procedural planning and optimized deployment
• Personalized therapies tailored to genetic and clinical profiles

Summary

Drug-eluting stents remain the cornerstone of PCI in coronary heart disease due to robust evidence showing reduced restenosis and repeat revascularization rates with favorable safety. Contemporary DES technologies (second generation and beyond) offer enhanced biocompatibility, thinner struts, and improved polymers, translating into lower stent thrombosis and superior clinical outcomes. Adjunctive management—particularly DAPT strategies—is tailored to patient risk profiles, and emerging technologies such as drug-coated balloons and bioresorbable scaffolds are expanding the therapeutic armamentarium. Ongoing innovation and long-term data will continue to refine DES use in diverse patient populations. INVAMED+1

DRUG-ELUTING STENTS (DES): 5 COLORED EXAM BOX POINTS

1️⃣ DES are the Default Strategy in CAD

• New-generation DES are Class I recommended for all PCI scenarios: stable CAD, ACS, diabetes, CKD, and complex lesions
• Bare-metal stents have no routine indication in contemporary practice
• Guideline consensus: ESC, ACC/AHA, CCS

2️⃣ New-Generation DES: Design Advantages

• Ultra-thin struts (≤80 µm) → less vessel injury, faster endothelialization
• Biocompatible or biodegradable polymers → reduced chronic inflammation
• Drugs: Everolimus, Zotarolimus, Sirolimus analogues

3️⃣ Safety: Stent Thrombosis Dramatically Reduced

• Very late stent thrombosis <0.5% at 5 years
• Polymer degradation + thinner struts = lower thrombogenicity
• Allows short DAPT (1–3 months) in high bleeding risk patients

4️⃣ Efficacy: Lower Restenosis Across All Subsets

• Target lesion failure significantly reduced vs BMS and early DES
• Proven benefit in:
  • Long lesions
  • Small vessels
  • Diabetes
  • CTOs and bifurcations

5️⃣ DAPT Individualization is Key

• Standard DAPT: 6 months (stable CAD), 12 months (ACS)
• Short DAPT (1 month) acceptable with contemporary DES in HBR
• DES performance now decoupled from prolonged DAPT necessity

📌 Exam Pearl

Modern DES combine high efficacy with excellent long-term safety, making them suitable even when antiplatelet therapy must be minimized.